Risk of Erythrocytosis during Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning from Two Clinical Cases

Journal of Clinical Endocrinology and Metabolism

Volumn 104, Issue 3, 2018, Pages 819-822

  Motta, Giovanna ^a,b   Zavattaro, Marco ^a   Romeo, Francesco ^b   Lanfranco, Fabio ^a   Broglio, Fabio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Diabetes and Endocrine Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; METFORMIN; SIMVASTATIN; TELMISARTAN; TESTOSTERONE UNDECANOATE; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BODY WEIGHT DISORDER; CASE REPORT; CLINICAL ARTICLE; CRYPTORCHISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; MALE; MEDICAL HISTORY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONSMOKER; OBESITY; ORCHIECTOMY; PATIENT MONITORING; PHLEBOTOMY; POSITIVE END EXPIRATORY PRESSURE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SLEEP DISORDERED BREATHING; TESTIS CANCER; ADVERSE EVENT; BLOOD; HORMONE SUBSTITUTION; POLYCYTHEMIA;

AGED; DIABETES MELLITUS, TYPE 2; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; POLYCYTHEMIA; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TESTOSTERONE;

EID: 85060968211     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2018-01702     Document Type: Article

References (10)

1. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77-85.
2. Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica. 2010;95(2):270-275.
3. Ferńandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-Analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575.
4. Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2015;38(1):103-112.
5. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018; 103(5):1715-1744.
6. European MedicinesAgency. Forxiga: EPAR-Product Information. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002322/WC500136026.pdf. Accessed 8 January 2018.
7. European Medicines Agency. Jardiance: EPAR-Product Information. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002677/WC500168592. pdf. Accessed 8 January 2018.
8. Ito M, Tanaka T. The anticipated renoprotective effects of sodiumglucose cotransporter 2 inhibitors. Intern Med. 2018;57(15): 2105-2114.
9. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8(12):844-847.
10. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018;41(7): 1516-1525.